Use of the Dye Stain Assay and Ultraviolet Light Test for Assessing Vaginal Insertion of Placebo-Filled Applicators Before and After Sex

Background Applicator dye staining and ultraviolet (UV) light have been used in trials to measure adherence, but not in the setting of before and after sex gel dosing (BAT-24). This study was designed to determine if semen or presex gel dosing impacts the sensitivity and specificity of a dye stain assay (DSA) for measuring vaginal insertion of placebo-filled applicators with BAT-24 dosing. Methods Healthy monogamous couples received Microlax-type applicators (Tectubes, Åstorp, Sweden) filled with hydroxyethylcelluose placebo gel. Women were instructed to vaginally insert 1 dose of gel before and a second dose after sex and to return applicators within 48 hours after sex. Applicators were stained to detect semen, followed by UV then DSA, and scored by 2 readers. Positive and negative controls were randomly included in applicator batches. Results Fifteen couples completed the study. Each woman returned at least 6 applicators over a 30-day period. The sensitivity for insertion of postsex applicators was higher for UV (97%) compared with DSA (90%), and the specificity was similar (≥96%). For presex applicators, the sensitivity and specificity were higher for DSA (100%) compared with UV testing (87% sensitivity, 96% specificity). Among returned postsex applicators, 95% tested positive by UV compared with 87% by DSA. Agreement between readers was significantly better on the presex applicators for DSA than for UV, and for postsex readings, agreement was less than half that for UV, although the results were not statistically significant. Conclusions Applicator tests are feasible for measuring adherence in trials with gel dosing before and after sex.

[1]  A. Minnis,et al.  Methodological Lessons from Clinical Trials and the Future of Microbicide Research , 2013, Current HIV/AIDS Reports.

[2]  B. Friedland,et al.  An Evaluation of Methods to Improve the Reporting of Adherence in a Placebo Gel Trial in Andhra Pradesh, India , 2013, AIDS and Behavior.

[3]  M. Einstein,et al.  Phase I Randomized Safety Study of Twice Daily Dosing of Acidform Vaginal Gel: Candidate Antimicrobial Contraceptive , 2012, PloS one.

[4]  Joelle M. Brown,et al.  Trypan blue staining to determine vaginal exposure in two types of plastic vaginal applicators containing two different microbicide formulations. , 2012, Sexually transmitted diseases.

[5]  C. Mauck,et al.  Dyeing to know: the use of vaginal applicator staining and other techniques to assess adherence to product use in microbicide trials. , 2012, Sexually transmitted diseases.

[6]  R. Cone,et al.  Evaluation of Microbicide Gel Adherence Monitoring Methods , 2012, Sexually transmitted diseases.

[7]  Kevin W P Miller,et al.  Developmental Validation of RSID™‐Semen: A Lateral Flow Immunochromatographic Strip Test for the Forensic Detection of Human Semen * , 2012, Journal of forensic sciences.

[8]  B. Mensch,et al.  Validation of a Dye Stain Assay for Vaginally Inserted Hydroxyethylcellulose-Filled Microbicide Applicators , 2011, Sexually transmitted diseases.

[9]  C. Hendrix,et al.  A Randomized Trial to Assess Anti-HIV Activity in Female Genital Tract Secretions and Soluble Mucosal Immunity Following Application of 1% Tenofovir Gel , 2011, PloS one.

[10]  P. Hewett,et al.  Assessing the Reporting of Adherence and Sexual Activity in a Simulated Microbicide Trial in South Africa: An Interview Mode Experiment Using a Placebo Gel , 2011, AIDS and Behavior.

[11]  Lynn Morris,et al.  Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women , 2010, Science.

[12]  S. Hillier,et al.  Limitations of the Dye-Based Method for Determining Vaginal Applicator Use in Microbicide Trials , 2009, Sexually transmitted diseases.

[13]  C. Mauck Biomarkers of semen exposure. , 2009, Sexually transmitted diseases.

[14]  B. Friedland,et al.  Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[15]  B. Herold,et al.  Assessment of Adherence to Product Dosing in a Pilot Microbicide Study , 2007, Sexually transmitted diseases.

[16]  D. Phillips,et al.  Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. , 2007, Contraception.

[17]  G. Doncel,et al.  In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. , 2005, AIDS research and human retroviruses.

[18]  J. Yuenger,et al.  ON HEALTH AND BEHAVIOR MEASUREMENT Program in Health and Behavior Measurement , 2004 .

[19]  D. Phillips,et al.  Assay for Establishing Whether Microbicide Applicators Have Been Exposed to the Vagina , 2004, Sexually transmitted diseases.

[20]  J. Malm,et al.  Semenogelin I and II, the predominant human seminal plasma proteins, are also expressed in non-genital tissues. , 2002, Molecular human reproduction.